Status:
COMPLETED
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions
Lead Sponsor:
Sandoz
Conditions:
Pain
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to demonstrate the relative bioequivalence of oxymorphone hydrochloride extended release tablets (Sandoz) with Opana extended release oxymorphone hydrochloride tablets.
Eligibility Criteria
Inclusion
- No clinically significant abnormal findings on physical exam, nonmedical history or clinical laboratory results on screening.
Exclusion
- Positive test results for HIV or hepatitis B or C
- Treatment for drug or alcohol abuse
- Allergy to opiates
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00857142
Start Date
November 1 2007
End Date
December 1 2007
Last Update
March 29 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.